ALNYLAM PHARMACEUTICALS, INC. Number of Reportable Segments
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. number of reportable segments for fiscal 2019 was 1.00 Segment, a 0.00% change from fiscal 2018.
- ALNYLAM PHARMACEUTICALS, INC. number of reportable segments for fiscal 2018 was 1.00 Segment, a 0.00% change from fiscal 2017.
- ALNYLAM PHARMACEUTICALS, INC. number of reportable segments for fiscal 2017 was 1.00 Segment.
Segment
| Period end | Number of Reportable Segments 12 month |
|---|---|
| 2019-12-31 | 1.00 Segment 10-K · filed 2020-02-13 |
| 2018-12-31 | 1.00 Segment 10-K · filed 2019-02-14 |
| 2017-12-31 | 1.00 Segment 10-K · filed 2018-02-15 |
segment
| Period end | Number of Reportable Segments 6 month | Number of Reportable Segments 12 month |
|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-07-30 | |
| 2023-12-31 | 1.00 segment 10-K · filed 2024-02-15 | |
| 2022-12-31 | 1.00 segment 10-K · filed 2023-02-23 | |
| 2021-12-31 | 1.00 segment 10-K · filed 2022-02-10 | |
| 2020-12-31 | 1.00 segment 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |